SAN DIEGO, Nov. 18, 2021 /PRNewswire/ — Tryp Therapeutics (CSE:TRYP;OTCQB:TRYPF) (“Tryp” or the “Company“), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it has received correspondence from the U.S. Food and Drug Administration (“FDA“) related to the Company’s Investigational New Drug (“IND“) application for a…


Previous articlePTSF85 – Ahmad Doroudian, Ph.D. of BetterLife Pharma and Dr. Abid Nazeer of Wesana Health
Next articlePsyBio Therapeutics Furthers Intellectual Property Portfolio with Six New Manufacturing Patent Applications